Therapy Areas: Hereditary Disorders
Proteostasis Therapeutics Proposes Public Offering of Common Stock
23 March 2018 - - Cambridge, Massachusetts-based clinical stage biopharmaceutical company Proteostasis Therapeutics, Inc. (NASDAQ: PTI) intends to offer and sell, subject to market and other conditions, 9m shares of its common stock in an underwritten public offering, the company said.
As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional 15%, or 1.35m shares, of the common stock offered in the public offering.
All of the shares to be sold in the offering are to be sold by Proteostasis.
Proteostasis is dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.
Login
Username:

Password:


Related Headlines